SutroVax is an independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases. Founded 2013 in Foster City, California, United States by Ash Khanna, Grant E. Pickering and Jeff Fairman, it is a developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.
SutroVax raises a $110,000,000 series D round from Janus Henderson Investors and RA Capital.
SutroVax raises a $85,000,000 series C round from Pivotal bioVenture Partners, Longitude Capital, Roche Venture Fund, Abingworth, CTI Life Sciences Fund, Frazier Healthcare Partners, Medicxi Ventures, TPG Growth and Foresite Capital.
SutroVax raises a $60,000,000 series B round from Pivotal bioVenture Partners, Longitude Capital, Roche Venture Fund, Abingworth, CTI Life Sciences Fund and Frazier Healthcare Partners.
Grant E. Pickering